Clinical Trial: Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085117) titled 'Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients' on June 30.

Brief Summary: The main objective of this study is to assess the number of participants with proptosis response as of last intravenous infusion of teprotumumab.

Study Start Date: July 02

Study Type: OBSERVATIONAL

Condition: Thyroid Eye Disease

Intervention: DRUG: Teprotumumab

Participants received teprotumumab as an intravenous (IV) infusion.

Recruitment Status: RECRUITING

Sponsor: Amgen

Published by HT Digital Content Services with permission from Health Daily Digest....